Investors Take Action as Pomerantz Law Firm Probes Pharming Group N.V. Claims

Investors on Alert: Pomerantz Law Firm Investigates Pharming Group N.V.

In a recent development that has sparked concerns among investors, the Pomerantz Law Firm has initiated an investigation into Pharming Group N.V. (NASDAQ: PHAR). This investigative move raises alarms for those who have financial interests in the company, particularly following a concerning announcement from Pharming regarding its drug application process. The investigation aims to determine whether Pharming and certain officers or directors have been involved in securities fraud or engaged in any unlawful business practices.

On February 1, 2026, Pharming issued a press release explaining that the U.S. Food and Drug Administration (FDA) had responded with a Complete Response Letter (CRL) concerning its supplemental New Drug Application (sNDA) for Joenja® (leniolisib). This medication is intended to treat children aged 4 to 11 years who have activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency condition.

The key issue identified by the FDA relates to the potential inadequate exposure levels for lower weight pediatric patients. The agency has requested additional pharmacokinetic data to reevaluate the proposed dosing for this age group. Additionally, there were concerns raised about one of the analytical methods used during the production batch testing, prompting the FDA to seek further data and clarifications on this matter.

In light of this news, Pharming's stock reacted sharply, with its American Depositary Receipt (ADR) price plummeting by $3.495 per ADR, a significant drop of 17.07%, closing at $16.975 per ADR the following day, February 2, 2026. This sharp decline has drawn significant attention, not only from investors but also from analysts and legal experts monitoring the situation.

The Pomerantz Law Firm, known for its work in corporate, securities, and antitrust litigation, emphasizes the importance of their investigation, urging investors who believe they may have been impacted to come forward. They can seek assistance by contacting Danielle Peyton at the firm. The firm has established a reputation for advocating for victims of securities fraud and firm misconduct, having recovered numerous substantial awards for class members in the past.

Founded by the late Abraham L. Pomerantz, the firm has played a pioneering role in the field of securities class actions for over 85 years. As one of the leading firms in this arena, their involvement signals a crucial moment for Pharming Group N.V. and its shareholders.

Investors are encouraged to stay informed and consider their positions carefully, especially in light of potential legal proceedings that may arise from the ongoing investigation. Joining the class action could provide a means for affected investors to seek restitution for losses incurred as a result of the circumstances surrounding Pharming's recent FDA response.

For those holding shares in Pharming or considering investing, the necessity of vigilance cannot be understated. The outcome of Pomerantz's inquiry may have lasting implications not only for Pharming's market standing but for the trust and confidence that investors place in the company's future.

In conclusion, as the situation unfolds, it remains essential for investors to engage with the available resources, including legal advice, to explore their rights and options in this potentially turbulent landscape. The Pomerantz Law Firm's investigation illustrates a critical juncture in which corporate governance and investor protection intersect, reminding stakeholders of the inherent risks within the pharmaceutical industry and the importance of transparency and adherence to regulatory standards.